U.S. Markets open in 6 hrs.

Array BioPharma Inc. (ARRY)


NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
7.86+0.06 (+0.77%)
At close: 4:00PM EDT
People also watch
EXELARQLCLDXRIGLFOLD
Full screen
Previous Close7.80
Open7.85
Bid0.00 x
Ask0.00 x
Day's Range7.69 - 7.96
52 Week Range3.10 - 13.40
Volume2,882,103
Avg. Volume3,468,100
Market Cap1.34B
Beta1.74
PE Ratio (TTM)-10.92
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Array BioPharma, Inc. breached its 50 day moving average in a Bearish Manner : ARRY-US : July 24, 2017
    Capital Cube2 days ago

    Array BioPharma, Inc. breached its 50 day moving average in a Bearish Manner : ARRY-US : July 24, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Array BioPharma, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bearish ... Read more (Read more...)

  • Zacks6 days ago

    New Strong Sell Stocks for July 20th

    Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

  • American City Business Journals8 days ago

    Colorado biotech makes deal with industry giant

    A Boulder biotech said it's made a deal with an industry giant to develop drugs for autoimmune disorders. Array BioPharma Inc. (ARRY) said it's made a deal with giant Amgen Inc. (AMGN) of Thousand Oaks, California to take advantage of Array's inflammatory disease discoveries. "The identification of this novel target, along with our team's deep experience in kinase inhibitor chemistry, gives us confidence that our efforts will result in a drug which will address a significant unmet medical need for patients with inflammatory disease," said Nicholas Saccomano, chief scientific officer at Array, in a statement.